PF-07934040 + pembrolizumab + platinum-based chemotherapy

PF-07934040 + pembrolizumab + platinum-based chemotherapy is an investigational combination regimen designed for the treatment of advanced solid tumors with KRAS mutations. PF-07934040 is a small molecule oral pan-KRAS inhibitor developed by Pfizer, intended to target a broad spectrum of KRAS mutant cancers by blocking KRAS-mediated signaling. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing T cell-mediated immune responses against cancer cells. Platinum-based chemotherapy agents (such as cisplatin, carboplatin, or oxaliplatin) induce DNA damage in rapidly dividing tumor cells, leading to apoptosis. This combination is being studied in Phase 1 clinical trials for efficacy and safety in cancers including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer with KRAS mutations, administered orally (PF-07934040) and intravenously (pembrolizumab and platinum agents)[1][2][4][5].